Article
Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy - 1 Dec 1999
Corbett J W, Ko S S, Rodgers J D, Jeffrey S, Bacheler L T, Klabe R M, Diamond S, Lai C M, Rabel S R, Saye J A, Adams S P, Trainor G L, Anderson P S, Erickson-Viitanen S K
Abstract excerpt
A research program targeted toward the identification of expanded-spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetics consistent with once-a-day dosing has resulted in the identification of the 4-cyclopropylalkynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)quinazolinones DPC 961 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.